DRI12544 (18+ years), QUEST (12+ years), VOYAGE (6-11 years)1
The most common adverse reactions from the DUPIXENT asthma trials were injection site reactions,q oropharyngeal pain, and eosinophilia.r These adverse reactions occurred in ≥1% of patients receiving DUPIXENT + SOC and at a higher rate than in patients receiving placebo + SOC in DRI12544 and QUEST (6-month safety pool).1
The safety profile of DUPIXENT in children 6-11 years of age with moderate-to-severe asthma through Week 52 was similar to the safety profile from studies in adult and pediatric subjects 12 years of age and older with moderate-to-severe asthma with the addition of helminth infections.1
qInjection site reactions cluster includes erythema, edema, pruritus, pain, and inflammation.1
rNone met the criteria for serious eosinophilic conditions.1